H-T. Arkenau

Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

L. Dirix, István Takács, Petros Nikolinakos et al. · Cancer Research · 2016 · 108 citations

Medicine, Oncology, Pharmacotherapy +17

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

T. Doi, Minesh Patel, G.S. Falchook et al. · Annals of Oncology · 2022 · 39 citations

Pharmacy, Oncology, Pharmacology +14

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

E.P. Hamilton, Charles L. Shapiro, Valentina Boni et al. · Annals of Oncology · 2022 · 36 citations

Medicine, Oncology, Pharmacology +17

728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors

Omer Abdul Hamid, T. Sato, D. Davar et al. · Annals of Oncology · 2022 · 25 citations

Medicine, Immunology, Oncology +12

161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Andrew Tutt, Zbigniew Nowecki, R. Szoszkiewicz et al. · Annals of Oncology · 2022 · 21 citations

Medicine, Oncology, Pharmacology +14